Eris Lifesciences [ERIS] vs Sun Pharmaceutical [SUNPHARMA] Detailed Stock Comparison
Eris Lifesciences
NSE
Loading...
Sun Pharmaceutical
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Eris Lifesciences wins in 5 metrics, Sun Pharmaceutical wins in 15 metrics, with 0 ties. Sun Pharmaceutical appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Eris Lifesciences | Sun Pharmaceutical | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 57.52 | 36.74 | Sun Pharmaceutical |
| Price-to-Book Ratio | 7.75 | 5.30 | Sun Pharmaceutical |
| Debt-to-Equity Ratio | 75.74 | 3.26 | Sun Pharmaceutical |
| PEG Ratio | 1.38 | -1.89 | Sun Pharmaceutical |
| EV/EBITDA | 23.19 | 23.33 | Eris Lifesciences |
| Profit Margin (TTM) | 13.17% | 19.29% | Sun Pharmaceutical |
| Operating Margin (TTM) | 26.73% | 24.34% | Eris Lifesciences |
| EBITDA Margin (TTM) | 26.73% | 24.34% | Eris Lifesciences |
| Return on Equity | 10.75% | 15.08% | Sun Pharmaceutical |
| Return on Assets (TTM) | 5.00% | 11.87% | Sun Pharmaceutical |
| Free Cash Flow (TTM) | $9.10B | $119.44B | Sun Pharmaceutical |
| Dividend Yield | 0.41% | 1.26% | Sun Pharmaceutical |
| 1-Year Return | 20.31% | -14.60% | Eris Lifesciences |
| Price-to-Sales Ratio (TTM) | 7.57 | 7.11 | Sun Pharmaceutical |
| Enterprise Value | $248.15B | $3,578.34B | Sun Pharmaceutical |
| EV/Revenue Ratio | 8.45 | 6.65 | Sun Pharmaceutical |
| Gross Profit Margin (TTM) | 76.07% | 79.58% | Sun Pharmaceutical |
| Revenue per Share (TTM) | $216 | $224 | Sun Pharmaceutical |
| Earnings per Share (Diluted) | $28.25 | $43.39 | Sun Pharmaceutical |
| Beta (Stock Volatility) | -0.02 | 0.31 | Eris Lifesciences |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Eris Lifesciences vs Sun Pharmaceutical Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Eris Lifesciences | 2.46% | -0.12% | -8.31% | -3.08% | 16.90% | 22.05% |
| Sun Pharmaceutical | -0.31% | 2.80% | 3.33% | -2.89% | -7.84% | -13.69% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Eris Lifesciences | 20.31% | 124.37% | 213.54% | 170.14% | 170.14% | 170.14% |
| Sun Pharmaceutical | -14.60% | 70.78% | 218.03% | 80.00% | 690.16% | 2,608.73% |
News Based Sentiment: Eris Lifesciences vs Sun Pharmaceutical
Eris Lifesciences
News based Sentiment: MIXED
September brought a blend of positive financial results and strategic moves (Brazil expansion, new market targets) alongside some operational concerns (operating profit decrease, stock volatility) and mixed analyst opinions. This creates a complex investment picture, making it a significant month for the company's trajectory.
Sun Pharmaceutical
News based Sentiment: MIXED
October was a mixed month for Sun Pharma, with a significant acquisition balanced against a decline in net profit. Positive analyst ratings and tariff news provide offsetting positive signals, making it a month of notable, but not overwhelmingly positive, developments for investors.
Performance & Financial Health Analysis: Eris Lifesciences vs Sun Pharmaceutical
| Metric | ERIS | SUNPHARMA |
|---|---|---|
| Market Information | ||
| Market Cap | ₹226.91B | ₹3.92T |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 156,272 | 2,839,112 |
| 90 Day Avg. Volume | 126,332 | 2,655,594 |
| Last Close | ₹1,624.90 | ₹1,631.20 |
| 52 Week Range | ₹1,097.20 - ₹1,910.00 | ₹1,548.00 - ₹1,952.25 |
| % from 52W High | -14.93% | -16.45% |
| All-Time High | ₹1,910.00 (Jun 09, 2025) | ₹1,960.35 (Sep 30, 2024) |
| % from All-Time High | -14.93% | -16.79% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.08% | 0.10% |
| Quarterly Earnings Growth | 0.42% | -0.20% |
| Financial Health | ||
| Profit Margin (TTM) | 0.13% | 0.19% |
| Operating Margin (TTM) | 0.27% | 0.24% |
| Return on Equity (TTM) | 0.11% | 0.15% |
| Debt to Equity (MRQ) | 75.74 | 3.26 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹209.63 | ₹300.99 |
| Cash per Share (MRQ) | ₹15.09 | ₹108.88 |
| Operating Cash Flow (TTM) | ₹7.57B | ₹110.84B |
| Levered Free Cash Flow (TTM) | ₹3.52B | ₹109.29B |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.41% | 1.26% |
| Last 12-Month Dividend | ₹7.35 | ₹21.00 |
Valuation & Enterprise Metrics Analysis: Eris Lifesciences vs Sun Pharmaceutical
| Metric | ERIS | SUNPHARMA |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 57.52 | 36.74 |
| Forward P/E | 39.01 | 48.79 |
| PEG Ratio | 1.38 | -1.89 |
| Price to Sales (TTM) | 7.57 | 7.11 |
| Price to Book (MRQ) | 7.75 | 5.30 |
| Market Capitalization | ||
| Market Capitalization | ₹226.91B | ₹3.92T |
| Enterprise Value | ₹248.15B | ₹3.58T |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 8.45 | 6.65 |
| Enterprise to EBITDA | 23.19 | 23.33 |
| Risk & Other Metrics | ||
| Beta | -0.02 | 0.31 |
| Book Value per Share (MRQ) | ₹209.63 | ₹300.99 |
Financial Statements Comparison: Eris Lifesciences vs Sun Pharmaceutical
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ERIS | SUNPHARMA |
|---|---|---|
| Revenue/Sales | ₹7.72B | ₹137.86B |
| Cost of Goods Sold | ₹1.85B | ₹28.15B |
| Gross Profit | ₹5.87B | ₹109.71B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹2.06B | ₹33.72B |
| EBITDA | ₹2.80B | ₹47.66B |
| Pre-Tax Income | ₹1.61B | ₹31.73B |
| Income Tax | ₹360.00M | ₹8.70B |
| Net Income (Profit) | ₹1.25B | ₹22.93B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ERIS | SUNPHARMA |
|---|---|---|
| Cash & Equivalents | ₹2.00B | ₹102.69B |
| Total Current Assets | ₹12.23B | ₹526.24B |
| Total Current Liabilities | ₹13.81B | ₹181.94B |
| Long-Term Debt | ₹17.82B | ₹3.58B |
| Total Shareholders Equity | ₹32.72B | ₹724.86B |
| Retained Earnings | ₹27.93B | ₹578.62B |
| Property, Plant & Equipment | ₹2.36B | ₹100.36B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ERIS | SUNPHARMA |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | ERIS | SUNPHARMA |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 156,272 | 2,839,112 |
| Average Daily Volume (90 Day) | 126,332 | 2,655,594 |
| Shares Outstanding | 136.16M | 2.40B |
| Float Shares | 40.85M | 1.04B |
| % Held by Insiders | 0.69% | 0.56% |
| % Held by Institutions | 0.21% | 0.25% |
Dividend Analysis & Yield Comparison: Eris Lifesciences vs Sun Pharmaceutical
| Metric | ERIS | SUNPHARMA |
|---|---|---|
| Last 12-Month Dividend | ₹7.35 | ₹21.00 |
| Last 12-Month Dividend Yield | 0.41% | 1.26% |
| 3-Year Avg Annual Dividend | ₹4.90 | ₹14.67 |
| 3-Year Avg Dividend Yield | 0.82% | 0.46% |
| 3-Year Total Dividends | ₹14.70 | ₹44.00 |
| Ex-Dividend Date | Feb 13, 2025 | Jul 07, 2025 |